Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Recruiting now · Phase 1

Conditions studied: Unresectable Metastatic Colorectal Cancer

In brief

The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment.

Key facts

Study ID

NCT04991948

Run by

Celyad Oncology SA

People needed

34

Starts

2021-11-22

Expected to finish

2038-05-25

Last updated by the study team

2022-03-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UZ Antwerpen — Edegem, Belgium (enrolling)
• UZ Leuven — Leuven, Belgium (enrolling)
• Mayo Clinic — Jacksonville, Florida, United States
• Moffit Cancer Center — Tampa, Florida, United States
• UZ Gent — Ghent, Belgium

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.